Inhibitory PARP v léčbě mozkových metastáz u pacientek s karcinomem prsu

Zdroj zde

The Impact of Dietary Supplement Use on Survival Outcomes in Breast Cancer

Published in Metastatic Breast Cancer and 

2 other channels 

Journal Scan / Research · January 08, 2020

TAKE-HOME MESSAGE

• In this observational correlative study, the authors evaluated the impact of dietary supplements during cancer treatment in 1134 patients with metastatic breast cancer queried at registration and during treatment in a randomized phase III trial of chemotherapy treatment schedules.

• The authors found a signal of potential negative impact in terms of recurrence and overall survival with the use of antioxidants, iron, and vitamin B12 during chemotherapy. Multivitamin use was not associated with survival outcomes.

High BMI May Cut Overall Survival in HER2+ Metastatic Breast Cancer

BMI had no impact on progression-free survival to first-line chemotherapy

HealthDay News-- For patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) treated with pertuzumab and/or trastuzumab emtansine (T-DM1), a body mass index (BMI) of ≥30 kg/m² is associated with worse overall survival but does not affect progression-free survival to first-line chemotherapy (PFS1), according to a study published online Jan. 15 in the Journal of Cellular Physiology.

Eriseld Krasniqi, M.D., from the IRCCS Regina Elena National Cancer Institute in Rome, and colleagues examined the influence of BMI on clinical outcomes of 709 patients with HER2+ mBC treated with pertuzumab and/or T-DM1. The influence of BMI was further analyzed among 575 women who progressed to first-line chemotherapy.

The researchers found that BMI had no impact on PFS1 overall, while BMI ≥30 kg/m² was associated with significantly worse overall survival. BMI ≥30 kg/m² had a detrimental effect on overall survival for the women within PFS1 quartile I (PFS1 no more than six months) in a univariate analysis. In a multivariable analysis, the results were confirmed. According to PFS1 quartiles, within six months of therapy, a higher percentage of patients with high BMI and low disease burden progressed.

"In this particularly challenging battlefield, namely, in the HER2+ metastatic breast cancer, a well-depicted patient profile, including details on body mass index and its prognostic relevance, can help inform therapeutic decisions," Krasniqi said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text 

Dietary Modification May Impact Breast Cancer Mortality

Journal of Clinical Oncology

Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial

J. Clin. Oncol 2020 Feb 07;[EPub Ahead of Print], RT Chlebowski, AK Aragaki, GL Anderson, K Pan, ML Neuhouser, JE Manson, CA Thomson, Y Mossavar-Rahmani, DS Lane, KC Johnson, J Wactawski-Wende, L Snetselaar, TE Rohan, J Luo, A Barac, RL Prentice

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

TAKE-HOME MESSAGE

• The authors provide a long-term follow-up analysis of the randomized Women’s Health Initiative Dietary Modification clinical trial evaluating the impact of a low-fat dietary pattern on breast cancer. After almost 20 years of follow-up, the significant reduction in deaths after breast cancer associated with the low-fat diet was persistent, and a significant reduction in deaths as a result of breast cancer was seen.

• These findings provide evidence that a low-fat dietary change in postmenopausal women may reduce the risk of dying as a result of breast cancer.

Management of Male Breast Cancer: ASCO Guideline

DOI: 10.1200/JCO.19.03120 Journal of Clinical Oncology

Published online February 14, 2020.

PMID: 32058842

celý článek zde

Kdy geneticky testovat?

V současné době jsou základními kritérii k testování syndromu následující:

a) Sporadický výskyt:

• bilaterálního karcinomu prsu, výskyt do 50 let věku, nebo oba do 60 let;
• unilaterálního karcinomu prsu do 45 let věku (do 50 let, pokud není vůbec známá rodinná anamnéza);
• všech epitelových karcinomů ovarií, karcinomů vejcovodů a peritoneálních karcinomů bez věkové limitace;
• duplicity nádoru prsu a ovaria bez věkové limitace;
• nádoru prsu u muže bez věkové limitace;
• medulárního karcinomu prsu (do 60 let věku u sporadického výskytu);
• ER–, PR–, ErbB2–, tzv. triple negativního karcinomu prsu (do 60 let věku u sporadického nádoru);
• duplicity karcinomu prsu a slinivky v jakémkoliv věku.

b) Familiární výskyt:

• alespoň tří příbuzných s nádorem prsu bez věkové limitace;
• dvou příbuzných s nádorem prsu, z toho alespoň jednoho diagnostikovaného ve věku do 50 let (nebo oba do 60 let);
• karcinomu prsu do 50 let věku s přímým příbuzným s nádorem spojeným s HBOC (prostaty, slinivky).

Zdroj:Prolekare

Novinky v diagnostice a léčbě karcinomu prsu – co zajímavého zaznělo na BOD 2019 | proLékaře.cz

Novinky v diagnostice a léčbě karcinomu prsu – co zajímavého zaznělo na BOD 2019 | proLékaře.cz: Novinky v diagnostice a léčbě karcinomu prsu – co zajímavého zaznělo na BOD 2019 | proLékaře.cz